19488 Federal Register / Vol. 70, No.
70 / Wednesday, April 13, 2005 / Notices
will be sent to all grantees after the
awards are made.
VII. Agency Contacts
Program Office Contact: Katherine
Gray, U.S. Department of Health and
Human Services, Administration for
Children and Families, ACYF—Head
Start Bureau, 330 C Street SW., Switzer
Room 2211, Washington, DC 20447,
Phone: 312–353–2260, E-mail:
kgray@acf.hhs.gov.
Grants Management Office Contact:
Delores Dickenson, U.S. Department of
Health and Human Services,
Administration for Children and
Families, ACYF—Head Start Bureau,
330 C Street SW., Switzer Room 2220,
Washington, DC 20447, Phone: 202–
260–7622, E-mail:
dedickenson@acf.hhs.gov.
VIII. Other Information
Applicants will not be sent
acknowledgements of received
applications.
Notice: Beginning with FY 2006, the
Administration for Children and
Families (ACF) will no longer publish
grant announcements in the Federal
Register. Beginning October 1, 2005,
applicants will be able to find a
synopsis of all ACF grant opportunities
and apply electronically for
opportunities via: http://
www.Grants.gov. Applicants will also be
able to find the complete text of all ACF
grant announcements on the ACF Web
site located at: http://www.acf.hhs.gov/
grants/index.html.
Dated: March 31, 2005.
Joan E. Ohl,
Commissioner, Administration on Children,
Youth and Families.
[FR Doc. 05–7030 Filed 4–12–05; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0059]
Withdrawal of Approval of a New
Animal Drug Application;
Dichlorophene and Toluene Capsules
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is withdrawing
approval of a new animal drug
application (NADA) for dichlorophene
and toluene capsules used in dogs and
cats for removal of certain intestinal
parasites. In a final rule published
VerDate jul<14>2003 18:37 Apr 12, 2005 Jkt 205001
elsewhere in this issue of the Federal
Register, FDA is amending the animal
drug regulations to remove portions
reflecting approval of this NADA.
DATES: Withdrawal of approval is
effective April 25, 2005.
FOR FURTHER INFORMATION CONTACT:
Pamela K. Esposito, Center for
Veterinary Medicine (HFV–212), Food
and Drug Administration, 7519 Standish
Pl., Rockville, MD 20855, 301–827–
7818, e-mail: pesposit@cvm.fda.gov.
SUPPLEMENTARY INFORMATION: Natchez
Animal Supply Co., 201 John R. Junkin
Dr., Natchez, MS 39120, has requested
that FDA withdraw approval of NADA
121–557 for THR Worm (dichlorophene
and toluene) Capsules used in dogs and
cats for removal of certain intestinal
parasites. This action is requested
because the product is no longer
manufactured or marketed.
Therefore, under authority delegated
to the Commissioner of Food and Drugs
(21 CFR 5.10), redelegated to the Center
for Veterinary Medicine (21 CFR 5.84),
and in accordance with 21 CFR 514.115
Withdrawal of approval of applications,
notice is given that approval of NADA
121–557 and all supplements and
amendments thereto, is hereby
withdrawn, effective April 25, 2005.
In a final rule published elsewhere in
this issue of the Federal Register, FDA
is amending the animal drug regulations
to reflect the withdrawal of approval of
this NADA.
Dated: March 31, 2005.
Catherine P. Beck,
Acting Director, Center for Veterinary
Medicine.
[FR Doc. 05–7338 Filed 4–12–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Request for Nominations for Voting
Consumer Representative Members on
Public Advisory Committees
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is requesting
nominations for voting consumer
representatives to serve on its advisory
committees that are under the purview
of the Center for Drug Evaluation and
Research (CDER).
FDA has a special interest in ensuring
that women, minority groups, and
individuals with disabilities are
adequately represented on its advisory
PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\13APN1.SGM
committees and, therefore, encourages
nominations of qualified candidates
from these groups.
DATES: Nominations will be accepted for
current vacancies and for those that will
or may occur through December 31,
2005. Because vacancies occur on
various dates throughout the year, there
is no cutoff date for the receipt of
nominations.
ADDRESSES: All nominations should be
sent to the contact person listed in the
FOR FURTHER INFORMATION CONTACT
section of this document.
FOR FURTHER INFORMATION CONTACT: Igor
Cerny, Center for Drug Evaluation and
Research (HFD–21), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, Maryland 20857, 301–827–
7001, e-mail: cerny@cder.fda.gov.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for voting
consumer representatives to all of its
advisory committees identified in
section I of this document.
I. Functions
The functions of advisory committees
under the purview of CDER are listed in
the following paragraphs.
A. Arthritis Advisory Committee
The committee reviews and evaluates
data concerning the safety and
effectiveness of marketed and
investigational human drug products for
use in the treatment of arthritis,
rheumatism, and related diseases and
makes appropriate recommendations to
the Commissioner of Food and Drugs
(the Commissioner).
B. Anti-Infective Drugs Advisory
Committee
The committee reviews and evaluates
available data concerning the safety and
effectiveness of marketed and
investigational human drug products for
use in the treatment of infectious
diseases and disorders and makes
appropriate recommendations to the
Commissioner.
C. Cardiovascular and Renal Drugs
Advisory Committee
The committee reviews and evaluates
available data concerning the safety and
effectiveness of marketed and
investigational human drug products for
use in the treatment of cardiovascular
and renal disorders and makes
appropriate recommendations to the
Commissioner.
D. Dermatologic and Ophthalmic Drugs
Advisory Committee
The committee reviews and evaluates
available data concerning the safety and
13APN1